Menu
webinara overview
Entrepreneurship

Webinar: Achieving Continued Value Creation or Exits for Your Biotech Startup

Strategic deals, IPOs & later-stage private equity investment

webinar description

Successfully starting a biotech company is just the beginning of a long journey. The company must navigate their product successfully through development stages, demonstrating that each step along the way is hitting key milestones and creating value inflections for the company. Various pathways exist for generating continued value for investors or to move toward a successful exit. Once the company has successfully deployed early capital and advanced a program, it needs to determine the tradeoffs of continued private equity capital, taking the company through an IPO, strategic partnership or a strategic sale to a biopharma company.

There are thousands of biotech companies all in search of continued value creation and successful exits, but only the ones who have compelling and convincing data can demand the outsized value and healthy returns for shareholders. Our expert panelists have enabled continued value creation and exits for biotech startups through strategic deals, IPOs and later stage private equity investment and will speak about the things they look for when supporting these startups to success.

Reasons to attend the webinar:
  • Learn from the experts on what they look for when supporting startups to success

  • Once a startup has successfully deployed early capital and advanced a program, it needs to determine the tradeoffs of continued private equity capital, taking the company through an IPO, strategic partnership or a strategic sale to a biopharma company

  • There are thousands of biotech companies all in search of continued value creation and successful exits, but only the ones who have compelling and convincing data can demand the outsized value and healthy returns for shareholders

Who should attend:

People in the biotech, life sciences, and pharma sector; entrepreneurs

Speakers:
Xontogeny
Chris Garabedian, Chairman & CEO
Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept, and formed a partnership with Perceptive in 2017 to establish the firm’s venture fund strategy. As a member of the Perceptive Investment Team, Chris will help source and identify venture opportunities for investment as part of the Xontogeny portfolio and beyond. Chris has a broad base of experience and a track record of success across his 25 years in the pharma and biotech industries, including at two of the most successful biopharma companies over the last 20 years, Gilead and Celgene. Most recently, Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris served as VP of Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global leadership roles at Gilead from 1997 to 2005, including as VP of Corporate Development, VP of Medical Affairs and VP of Marketing. Chris is currently on the Board of Directors of MassBio, on the Board of Advisors for the Keck Graduate Institute and serves as a Senior Advisor for the Boston Consulting Group.
UBS Oncology Impact Fund, MPM Capital
Christiana Bardon, Partner
Christiana Bardon is a partner of the UBS Oncology Impact Fund managed by MPM Capital, an investment fund dedicated to oncology therapeutics. She is also the manager of the Burrage Capital Fund. Previously, she was a health care analyst at Fidelity Investments covering biotechnology, life science tools and diagnostics. Dr. Bardon earned her MS/BS from MIT, her MD magna cum laude from Harvard Medical School, and her MBA from Harvard Business School. While at Harvard Medical School, Christiana was the recipient of a Howard Hughes fellowship. She also completed a residency in internal medicine at the Brigham and Women’s Hospital. Dr. Bardon currently serves on the Board of Fellows at the Harvard Medical School.
KSQ Therapeutics
George Golumbeski, Executive Advisor
George Golumbeski serves as Executive Advisor and board member of KSQ Therapeutics, and as a board member of Carrick Therapeutics. Mr. Golumbeski was previously Senior Vice President of Business Development for Celgene Corporation, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medications to patients suffering from cancer and/or chronic inflammation. In his 25-year career in this sector, Mr. Golumbeski has worked on medications for Parkinson’s disease, epilepsy, cancer, anemia, and Crohn’s disease. He is known globally within the biotechnology industry for his interest in leading-edge science, and his constructiveness in creating inter-company collaborations. He currently serves on the Board of Directors/Trustees of Acceleron Pharma, Enanta Pharmaceuticals, the Keck Graduate Institute, and the National Audubon Society. He received a B.A. in Biology from the University of Virginia, a Ph.D. in Genetics from the University of Wisconsin-Madison, and conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder.
Leerink
Jon Civitarese, Managing Director
Jon Civitarese was one of the firm’s earliest employees when he joined Leerink Partners LLC in 1995, providing advisory services to high-net-worth individuals in the Private Client Group prior to moving to Investment Banking. Since 1999, his activities have included advising public and private life science companies on strategic initiatives and equity capital financings as part of Leerink’s investment banking team. In addition to his primary banking responsibilities, he has also served as a senior member of the equity capital markets and syndicate team since 2001.

Jon began his career by serving in the U.S. Army as an infantry soldier, and later graduated from the University of Maine.
23

May

2018

1:00 - 2:00 PM
(GMT -4)

(Duration - 60 minutes)

ATTENDANCE FEE - FREE

WEBINAR HAS ENDED
Organizer: Xconomy

Xconomy is dedicated to providing business and technology leaders with timely, insightful, close-to-the-scene information about the local personalities, companies, and technological trends that best exemplify today’s high-tech economy. We are the authoritative voice on the exponential economy, ...
Read More

Other webinars you may like
Free
Sep 26, 2.00 PM (GMT +02:00)
Explore and discover Cass Business School MBAs
The Cass Full-time MBA is ranked the top 1-year programme in London, 5th globally for entrepreneurship and 8th globally for corporate strategy (Financial Times, 2018). The Cass Executive MBA is ranked 11th in Europe and for career progression is number one in the UK (Financial Times, 2017). Join Alex
Cass Business School
Speaker - Alex Jones
More info
Free
Oct 12, 10.00 AM (GMT -07:00)
The AI Readiness Checklist
Learn what your enterprise needs to do to prepare for the Intelligent Era. Join Adrian Bowles, Lead Analyst for AI at Aragon Research, as he overview three major areas to assess for AI readiness and explores the important considerations for each: 1. People: for developers and users, we’ll
Aragon Research
Speaker - Adrian Bowles
More info
Free
Duration: 60 Min
How to Make the Right Decision for your IoT Application
Join KORE for an educational webinar that will provide the information necessary for IoT companies that need to make the fundamental “build vs. buy” decision. As part of it’s “DNA” – device, network, and application – any IoT solution needs a “thing”,
IoT Now Magazine
Speaker - George Malim
More info
Other webinars you may like
Free
Duration: 60 Min
How to Make the Right Decision for your IoT Application
Join KORE for an educational webinar that will provide the information necessary for IoT companies that need to make the fundamental “build vs. buy” decision. As part of it’s “DNA” – device, network, and application – any IoT solution needs a “thing”,
IoT Now Magazine
Speaker - George Malim
More info
Free
Duration: 60 Min
How to Thrive in This Business Environment
In today’s Amazon-impacted marketplace, customers expect rapid deliveries and 24/7 accessibility at low prices. Executives are turning previous notions about offshoring upside down. They are re-evaluating their supply chains – should they continue offshoring to obtain lower labor costs?
TalentStream
Speaker - Scott Luton
More info
show all webinars
ARE YOU 100% SURE YOU WANT TO YOU WANT TO DISCONNECT ?

yes no
PLEASE TYPE A VALID KEYWORD IN THE SEARCH FIELD